1. Academic Validation
  2. Roxadustat ameliorates vascular calcification in CKD rats by regulating HIF-2α/HIF-1α

Roxadustat ameliorates vascular calcification in CKD rats by regulating HIF-2α/HIF-1α

  • Environ Toxicol. 2023 Dec 29. doi: 10.1002/tox.24116.
Yujing Wang 1 Min Xiao 2 Feng Cai 3 Yang Li 4 Tianli Shi 4 Xiaoyan Zhou 1 Shuhong Tian 5 Denggao Huang 6
Affiliations

Affiliations

  • 1 Department of Hemodialysis, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou, China.
  • 2 Department of Clinical Laboratory, Strategic Support Force Medical Center, Beijing, China.
  • 3 Department of Scientific Research, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou, China.
  • 4 Department of Nephrology, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou, China.
  • 5 Research Center for Drug Safety Evaluation of Hainan Province, Hainan Medical University, Haikou, China.
  • 6 Department of Central Laboratory, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou, China.
Abstract

Vascular calcification (VC) is a common complication of chronic kidney disease (CKD). VC is a gene-regulated process similar to osteogenic differentiation. There are still no convincing schemes to prevent and reduce the development of VC. It has been reported that hypoxia-inducing factor 1α (HIF-1α) and endothelin-1(ET-1) are related to VC. In this study, we found that the expression of ET-1 and HIF-1α was enhanced after VC, the interaction between HIF-1α and ET-1 was confirmed by CO-IP and luciferase experiments. We found that ET-1 was an upregulated differential gene of calcified vascular smooth muscle cells (VSMCs) through gene sequencing. However, hypoxia-inducing factor 2α (HIF-2α) and HIF-1α have antagonistic effects on each other. HIF-1α is a pro-inflammatory cytokine, and HIF-2α can improve inflammation and fibrosis. Roxadustat, as a selective PHD3 inhibitor, preferentially activates HIF-2α. It is still unclear whether roxadustat improves VC in CKD by regulating the expression of HIF-2α/HIF-1α. Alizarin red staining and western blot as well as immunohistochemical results showed that roxadustat could significantly reduce the degree of vascular and VSMCs calcification in CKD rats. Serum HIF-1α and ET-1 were significantly decreased after roxadustat treatment. In addition, western blot results showed that roxadustat could decrease the expression of HIF-1α and ET-1 in vascular tissues and calcified VSMC, but HIF-2α expression significantly increased. Interestingly, our study confirmed that activation of HIF-1α or inhibition of HIF-2α reversed the ameliorating effect of roxadustat on VC, proving that the effect mediated by roxadustat is HIF-2α/HIF-1α dependent. We have demonstrated for the first time that roxadustat improves VC in CKD rats by regulating HIF-2α/HIF-1α, thus providing a new idea for the application of roxadustat in VC of CKD.

Keywords

endothelin-1; hypoxia-inducing factor 1α; hypoxia-inducing factor 2α; roxadustat; vascular calcification.

Figures
Products